Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Secukinumab - Novartis

Drug Profile

Secukinumab - Novartis

Alternative Names: AIN-457; Anti-interleukin 17A monoclonal antibody; Cosentyx; KB-03303A; Kosentikusu; NVP-AIN-457; Scapho

Latest Information Update: 06 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alcon; Novartis
  • Developer Beth Israel Deaconess Medical Center; GWT-TUD GmbH; Icahn School of Medicine at Mount Sinai; Novartis
  • Class Anti-inflammatories; Antiasthmatics; Antihyperglycaemics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action IL17A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-radiographic axial spondyloarthritis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Hidradenitis suppurativa; Non-radiographic axial spondyloarthritis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Registered Juvenile rheumatoid arthritis
  • Phase III Giant cell arteritis; Graves ophthalmopathy; Polymyalgia rheumatica; Rotator cuff injuries
  • Phase II Atopic dermatitis; Discoid lupus erythematosus; Necrobiosis lipoidica; SARS-CoV-2 acute respiratory disease; Tendon injuries
  • Discontinued Alopecia areata; Asthma; Crohn's disease; Dry eyes; Lichen planus; Lupus nephritis; Multiple sclerosis; Rheumatoid arthritis; Type 1 diabetes mellitus; Uveitis

Most Recent Events

  • 06 Feb 2024 Novartis plans to file a regulatory submission for Polymyalgia rheumatica in 2026 (Novartis pipeline, February 2024)
  • 31 Dec 2023 Discontinued - Phase-III for Lupus nephritis (Adjunctive treatment) in Spain, Australia, Brazil, Colombia, Philippines, Portugal, Slovakia, Thailand, Czech Republic, Guatemala, Japan, South Korea, Vietnam (SC)
  • 31 Dec 2023 Discontinued - Phase-III for Lupus nephritis (Combination therapy) in Germany, United Kingdom, Greece, USA, Peru, Australia, Brazil, Brazil, China, Colombia, Croatia, Czech Republic, Denmark, France, France, Guatemala, India, India, Italy, Japan, South Korea, Latvia, Mexico, Norway, Portugal, Philippines, Romania, Russia, Slovakia, Slovakia, South Africa, Spain, Spain, Sweden, Sweden, Switzerland, Taiwan, Thailand, Turkey, Vietnam, Chile (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top